The association between hypogammaglobulinemia severity and infection risk in rituximab-treated patients with childhood-onset idiopathic nephrotic syndrome-Reference-Cited by-同舟云学术

The association between hypogammaglobulinemia severity and infection risk in rituximab-treated patients with childhood-onset idiopathic nephrotic syndrome

Published:2022-06-24 Issue:2 Volume:38 Page:451-460
ISSN:0931-041X
Container-title:Pediatric Nephrology
language:en
Short-container-title:Pediatr Nephrol

Author:

Inoki Yuta,Nishi Kentaro,Sato Mai,Ogura Masao,Kamei Koichi^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Nephrology,Pediatrics, Perinatology and Child Health

Link

https://link.springer.com/content/pdf/10.1007/s00467-022-05652-9.pdf

Reference34 articles.

1. Kamei K, Ishikura K, Sako M, Aya K, Tanaka R, Nozu K, Kaito H, Nakanishi K, Ohtomo Y, Miura K, Takahashi S, Morimoto T, Kubota W, Ito S, Nakamura H, Iijima K (2017) Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab. Pediatr Nephrol 32:2071–2078. https://doi.org/10.1007/s00467-017-3718-0

2. Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y (2014) Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384:1273–1281. https://doi.org/10.1016/S0140-6736(14)60541-9

3. Trautmann A, Vivarelli M, Samuel S, Gipson D, Sinha A, Schaefer F, Hui NK, Boyer O, Saleem MA, Feltran L, Muller-Deile J, Becker JU, Cano F, Xu H, Lim YN, Smoyer W, Anochie I, Nakanishi K, Hodson E, Haffner D, International Pediatric Nephrology Association (2020) IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 35:1529–1561. https://doi.org/10.1007/s00467-020-04519-1

4. Kelesidis T, Daikos G, Boumpas D, Tsiodras S (2011) Does rituximab increase the incidence of infectious complications? A narrative review. Int J Infect Dis 15:e2–e16. https://doi.org/10.1016/j.ijid.2010.03.025

5. Christou EAA, Giardino G, Worth A, Ladomenou F (2017) Risk factors predisposing to the development of hypogammaglobulinemia and infections post-rituximab. Int Rev Immunol 36:352–359. https://doi.org/10.1080/08830185.2017.1346092

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of rituximab and risk factors for poor prognosis in patients with childhood-onset steroid-resistant nephrotic syndrome: a multicenter study;Pediatric Nephrology;2024-06-04

2. Efficacy of rituximab and risk factors for poor prognosis in patients with childhood-onset refractory steroid-resistant nephrotic syndrome: a multicenter study;2024-02-23

3. Efficacy and safety of long-term repeated use of rituximab in pediatric patients with nephrotic syndrome;Pediatric Nephrology;2023-09-08

4. Rituximab;Reactions Weekly;2023-07-22

5. Efficacy and safety of long-term repeated use of rituximab in pediatric patients with nephrotic syndrome;2023-05-17